THE SOLUTION WHAT YOU SEND A BUYER SHOWS 3 THINGS ABOUT YOU: 1. Your ability to organize your thoughts 2. Your understanding of the sales process (don’t overwhelm me and respect my time) 3. Your professionalism So when the request comes in: SEND ME SOMETHING, whether you send a little or a lot, you absolutely need a one page proposal. Provide a summary that captures all the key ideas and important value of your product BUT STILL LEAVES ROOM for conversation e.g. another meeting. A T D O LI R A S WHAT’S CHANGING? V These are conscious IPO In Healthcare, there are dozens of companies interested in the and subconscious M&A value proposition of ANTI-INFECTION TREATMENT. We have reasons to pay identified— and explore give segments where there is a clear M&A rationale EXIT ANALYSIS 1 attention. to acquisition. Over 50 companies are represented. THE PROBLEM WE ARE WORKING TO SOLVE KEY FEATURES HOSPITALS AND URGENT CARE FACILITIES RELY on two methods to handle infection. If either of these treatments don’t work, your chances of getting very High-margin, high EBITDA products IPO RATIONALE sick go up substantially. Zinc enables intercellular adhesion of the bacteria. Large new-customer pipeline >$1B Remove the zinc, and the bacteria cannot build its protective biofilm because Products are two generations ahead of the cellular building blocks won’t bind together. Without a protective competitive offerings ACME mechanism, bacteria is much more susceptible to antibiotics. Limited options to investors in the HPA segment 1. Remove It. 2. Kill It. 3. Cover it. In technical medical terms Dressings are used in an attempt IPO this is called It is and includes antibiotics applied to seal out bacteria and control debridement. the removal—that is surgically topically (creams or foams) or moisture content. Many come cutting out—of a patient’s dead, given intravenously. with additives to absorb excess damaged, or infected tissue. moisture or assist in healing. usa management team H IT’S A DIFFICULT INTERSECTION CAPITAL DEAL Mike Smith is the account Y O HEALTHCARE MARKET SIZE AND GROWTH executive for ACME and leads R O EXIT ANALYSIS SUMMARY $120B business development. T K PROBLEM TO SOLVE HIPA RELATED PRODUCTS [email protected] N S KEY INVESTMENT MERITS DETAIL 800-555-1212 E Immediately overcome LARGE PAYORS Dr. Smith is currently the UCLA Eminent SECTOR HEALTHCARE CONSUMER PRODUCTS Scholar of Medicine where he is a Professor in FOCUS EXIT ANLYSIS the Department of Molecular Biochemistry and rejection triggers by GEOGRAPHIC FOCUS LOS ANGELES Microbiology. Dr. Smith focuses his research in HEALTHCARE IT mechanistic studies of cellular adhesion and INVESTMENT FOCUS SHORT HOLD HIGH YIELD receptor-mediated signaling to include the confirming why this EXIT DATE 2020 LAB/DIAGNOSTICS study of bio receptor disease. He has over 40 TARGET SIZE $30M Peer Reviewed publications and 2 patents to his name.and a PhD in Molecular Biophysics 2 deal is worth spending MARKET SHARE TARGET $80M from Yale University and was a Postdoctoral time on. TARGET PROJECT COMMITMENT $5M Fellow at the California Institute of Technology. TIME TO CAPITAL MARKETS EVENT A R T R IV A E N KEY FEATURES Explains uniqueness and advantage in 3 plain English. A R T R IV A E TEAM N Snapshot of who is in charge and why 4 they are the right person to lead. Pitch Anything Blueprint 5